Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles
dc.contributor.author | Fontana, Robert J. | |
dc.contributor.author | Li, Yi‐ju | |
dc.contributor.author | Phillips, Elizabeth | |
dc.contributor.author | Saeed, Naba | |
dc.contributor.author | Barnhart, Huiman | |
dc.contributor.author | Kleiner, David | |
dc.contributor.author | Hoofnagle, Jay | |
dc.date.accessioned | 2021-08-03T18:16:07Z | |
dc.date.available | 2022-09-03 14:16:06 | en |
dc.date.available | 2021-08-03T18:16:07Z | |
dc.date.issued | 2021-08 | |
dc.identifier.citation | Fontana, Robert J.; Li, Yi‐ju ; Phillips, Elizabeth; Saeed, Naba; Barnhart, Huiman; Kleiner, David; Hoofnagle, Jay (2021). "Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles." Liver International (8): 1884-1893. | |
dc.identifier.issn | 1478-3223 | |
dc.identifier.issn | 1478-3231 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/168490 | |
dc.description.abstract | Background/AimsAllopurinol can cause HLA class I- associated life- threatening severe skin reactions. However, HLA risk and association with clinical features in allopurinol hepatotoxicity are unknown.MethodsEleven of 17 patients with suspected allopurinol hepatotoxicity enrolled into the Drug- Induced Liver Injury Network were adjudicated as definite, highly likely, or probable. High- resolution HLA sequencing was undertaken in cases and compared with population and other DILI controls.ResultMedian age was 60Â years, 54% were male, and 63% African- American, 27% Caucasian, and 9% Hispanic. Patients presented at a median of 52Â days after starting allopurinol, all were hospitalized and six were jaundiced. The median peak ALT, alkaline phosphatase, and total bilirubin were 525 U/L, 521 U/L, and 7.8Â mg/dl, respectively, with a median R ratio of 2.7 at onset. During follow- up, nine patients were treated with corticosteroids including five of the six with suspected DRESS. Three patients died including two from liver failure at 38 and 45Â days after onset, and the remaining eight recovered. Three HLA alleles were found to be overrepresented in allopurinol cases, particularly in African Americans: HLA- B*58:01, which has been previously linked to severe skin reactions, and HLA- B*53:01 and HLA- A*34:02, all of which are more frequently found in African Americans than European Americans or Latinos.ConclusionsAllopurinol hepatotoxicity is associated with systemic hypersensitivity, a short latency to onset, African- American race and three HLA risk alleles, HLA- B*58:01, HLA- B*53:01, and HLA- A*34:02- 58:01 testing may help confirm a diagnosis of hepatotoxicity in allopurinol- treated patients. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | genetic polymorphisms | |
dc.subject.other | gout | |
dc.subject.other | human leukocyte antigen | |
dc.subject.other | hyperuricaemia | |
dc.subject.other | liver injury | |
dc.title | Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/168490/1/liv14903.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/168490/2/liv14903_am.pdf | |
dc.identifier.doi | 10.1111/liv.14903 | |
dc.identifier.source | Liver International | |
dc.identifier.citedreference | Wu R, Cheng Y, Zhu L, et al. Impact of HLA- B*58:01 allele and allopurinol- induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. Oncotarget. 2016; 7: 81870 - 81879. | |
dc.identifier.citedreference | Vanderstigel M, Zafrani ES, Lejonc JL, Schaeffer A, Portos JL. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin- ring granulomas. Gastroenterol. 1986; 90: 188 - 190. | |
dc.identifier.citedreference | Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allopurinol. Singapore Med J. 2000; 41: 156 - 160. | |
dc.identifier.citedreference | Hung SI, Chung WH, Liou LB, et al. HLA- B*58:01 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci. 2005; 102: 4134 - 4139. | |
dc.identifier.citedreference | Kaniwa N, Saito Y, Aihara M, et al. JSAR research group. HLA- B locus in Japanese patients with anti- epileptics and allopurinol- related Stevens- Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008; 9: 1617 - 1622. | |
dc.identifier.citedreference | Lonjou C, Borot N, Sekula P, et al. RegiSCAR study group. A European study of HLA- B in Stevens- Johnson syndrome and toxic epidermal necrolysis related to five high- risk drugs. Pharmacogenet Genomics. 2008; 18: 99 - 107. | |
dc.identifier.citedreference | Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA- B*58:01 allele and allopurinol- induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta- analysis. BMC Med Genet. 2011; 12: 118. | |
dc.identifier.citedreference | Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug- Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32: 55 - 68. | |
dc.identifier.citedreference | Li YJ, Phillips E, Dellinger A, et al. HLA- B*14:01 and HLA- B*35:01 are associated with trimethoprim- sulfamethoxazole induced liver injury. Hepatology. 2020. | |
dc.identifier.citedreference | Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug- induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014; 59 ( 2 ): 661 - 670. | |
dc.identifier.citedreference | Kardaum SH, Sidoroff A, Valeyrie- Allanore L, et al. Variability in the clinical pattern of cutaneous side- effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007; 156: 609 - 611. | |
dc.identifier.citedreference | Zheng X, Shen J, Cox C, et al. HIBAG- HLA genotype imputation with attribute bagging. Pharmacogenomics J. 2014; 14: 192 - 200. | |
dc.identifier.citedreference | Cirulli ET, Nicoletti P, Abramson K, et al. A Missense variant in PTPN22 is a risk factor for Drug- induced liver injury. Gastroenterology. 2019; 156: 1707 - 1716. | |
dc.identifier.citedreference | Hoof I, Peters B, Sidney J, et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 2009; 61: 1 - 13. | |
dc.identifier.citedreference | Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002; 70: 425 - 434. | |
dc.identifier.citedreference | Drug usage Statistics. United States, 2007- 2017. 2020. https://clincalc.com | |
dc.identifier.citedreference | Chawla SK, Patel HD, Parrino GR, Soterakis J, Lopresti PA, D’Angelo WA. Allopurinol hepatotoxicity: case report and literature review. Art & Rheumatism. 1977; 20: 1546 - 1550. | |
dc.identifier.citedreference | Somjrua R, Eickman EE, Saokaew S, Lohntnavy M, Chaiyakunapruk N. Association of HLA- B*58:01 allele and allopurinol induced Stevens Johnson Syndrome and TEN: A systematic review and meta- analysis. BMC Med Genetics. 2011; 12: 118. | |
dc.identifier.citedreference | Lu N, Rai SK, Terkeltaub R, Kim SC, Menendez ME, Choi HK. Racial disparities in the risk of Stevens- Johnson syndrome and toxic epidermal necrolysis as urate- lowering drug adverse events in the United States. Sem Arth Rheum. 2016; 46: 253258. | |
dc.identifier.citedreference | Ko TM, Tsai CY, Chen SY, et al. Use of HLA- B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015; 351: h4848. | |
dc.identifier.citedreference | Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in the elderly and young subjects. Br J Clin Pharmacol. 1999; 48: 501 - 509. | |
dc.identifier.citedreference | Yun J, Marcaida MJ, Eriksson KK, et al. Oxypurinol directly and immediately activates the drug- specific T- cells via the preferential use of HLA- B*58:01. J Immunology. 2014; 192: 2984 - 2993. | |
dc.identifier.citedreference | Reuben A, Tillman H, Fontana RJ, et al. Outcomes in adults with acute liver failure between 1998 and 2013. Ann Intern Med. 2016; 164: 724 - 732. | |
dc.identifier.citedreference | Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins PW. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004; 10: 1018 - 10123. | |
dc.identifier.citedreference | Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug induced liver injury in the general population of Iceland. Gastroenterology. 2013; 144: 1419 - 1425.e3. | |
dc.identifier.citedreference | Andrade R, Lucena MI, Fernandez MC, et al. Drug induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10- year period. Gastroenterology. 2005; 129 ( 2 ): 512 - 521. | |
dc.identifier.citedreference | Fitzgerald JD, Dalbeth N, Mikulus T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020; 72: 744 - 760. | |
dc.identifier.citedreference | Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353: 2450 - 2461. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.